Hypocortisolemic clamp unmasks jointly feedforward- and feedback-dependent control of overnight ACTH secretion

Ali Iranmanesh and Johannes D Veldhuis
Endocrine Section, Department of Medicine, Salem Veterans Affairs Medical Center, Salem, Virginia 24153, USA and 1Endocrine Research Unit, Department of Internal Medicine, Mayo School of Graduate Medical Education, Clinical Translational Science Center, Mayo Clinic, Rochester, Minnesota 55905, USA
(Correspondence should be addressed to J D Veldhuis; Email: veldhuis.johannes@mayo.edu)

Abstract

Background: ACTH secretion is under hypothalamic stimulatory (feedforward) and adrenal inhibitory (feedback) control.
Hypothesis: Assessment of overnight ACTH secretion during a hypocortisolemic clamp will permit the estimation of changing feedforward and feedback.
Subjects: Seven healthy men.
Interventions: An oral dose of placebo (PLAC), metyrapone (METY, 3 g), or ketoconazole (KTCZ, 1.2 g) was given at midnight (MN) to block glucocorticoid synthesis. Plasma ACTH was sampled every 10 min (MN to 0800 h).
Results: Compared with PLAC, administration of METY and KTCZ reduced morning cortisol concentrations by 77 and 54% respectively (∗P<0.001). Hypocortisolemia elevated pulsatile ACTH secretion by 8.2- (METY) and 5.3-fold (KTCZ; both ∗∗P<0.001). Basal ACTH secretion rose by 3.4-fold under METY-induced cortisol depletion (∗P=0.020). ACTH secretory-burst shape and half-life were stable. ApEn of ACTH release declined overnight (∗P=0.021) and with the drug (∗∗P=0.001), denoting enhanced feedforward coordination.
Conclusion: The combined data predict overnight amplification and coordination of hypothalamic feedforward drive onto ACTH release. Therefore, disruption of either mechanism might contribute to clinical pathophysiology, such as late-day elevations of cortisol output in fasting, alcoholism, depression, or aging.
Methods

Subjects and protocol

Healthy unmedicated men (N=6 placebo (PLAC), N=7 for both drugs, range of age 35–52 years and body mass index 24–33 kg/m²) participated after providing written informed consent approved by the institutional review board of the Salem-Roanoke Veterans Affairs Medical Center. Each subject had an unremarkable medical history and physical examination, and normal screening tests of hepatic, renal, hematological, and endocrine thyroid-stimulating hormone (TSH, morning cortisol, insulin-like growth factor-I and testosterone) function. Volunteers underwent randomly ordered overnight sampling studies at least 2 weeks apart. Sessions entailed placement of a forearm i.v. catheter at 2200 h, and oral administration of PLAC, (METY 3 g), or ketoconazole (KTCZ 1.2 g) with a snack at midnight (MN). Both drugs lower cortisol concentrations, albeit via different sites of steroidogenic blockade, viz., CYP11B and CYP11A.

Figure 1 Time courses of plasma cortisol (top) and ACTH (bottom) concentrations in six healthy men sampled every 10 min from midnight (MN) to 0800 h. Each subject received oral PLAC, KTCZ, or METY at MN, as indicated. Data are the mean ± S.E.M.
respectively (9, 20). Thus, their use is complementary to verify that hypocortisolemia rather than drug type drives ACTH changes. Plasma was withdrawn every 10 min from MN to 0800 h in chilled EGTA-containing plastic tubes on ice and centrifuged immediately in the cold before freezing at −70 °C for later assay of ACTH and cortisol.

**Hormone assays**

ACTH and cortisol concentrations were measured by immunoradiometric and solid-phase RIA respectively, as described earlier (10, 11). Sensitivity was 2 ng/l for ACTH and 2 μg/dl (58 nmol/l) for cortisol. All samples from each subject were assayed in batch. Intraassay coefficient of variation (CV) values for ACTH and cortisol were 6.5 and 5.8% and interassay CV values 8.5 and 6.9% respectively.

**Deconvolution analysis**

Overnight ACTH concentration time series (total 8 h) were analyzed by way of a recently developed variable-waveform deconvolution method (19). The automated Matlab program first detrends and normalizes concentrations to the unit interval [0, 1] (18). Second, successive potential pulse-time sets are created by an incremental smoothing process (a nonlinear adaptation of the heat-diffusion equation), which deletes the least significant nadir one at a time. Third, maximum-likelihood expectation parameter estimation is used to calculate secretion and elimination rates simultaneously for each candidate pulse-time set. The model specifies basal secretion ($\beta_0$), a slow-phase half-life ($\alpha_2$), secretory-burst mass ($\eta_0$, $\eta_1$), random effects on burst mass ($\sigma_A$), procedural/measurement error ($\sigma_r$), and a three-parameter flexible Gamma probability distribution to embody secretory-burst waveform ($\beta_1$, $\beta_2$, $\beta_3$). The rapid phase half-life of ACTH was assumed to be 3.5 min representing 37% of total decay. And, fourth, the Akaike information criterion is applied to distinguish objectively among candidate pulse-time sets (21). Observed interpulse intervals are described by a two-parameter Weibull renewal process (more general form of a Poisson process). Units of parameters are burst frequency (number per 24 h, $\lambda$ of Weibull distribution), regularity of interpulse intervals (unitless $\gamma$ of Weibull), slow half-lives (min), basal and pulsatile secretion rates (concentration units/24 h), mass secreted per burst (concentration units), and waveform mode (time delay to maximal secretion after burst onset, min) (18, 19).

**ApEn analysis**

Approximate entropy, ApEn (1, 75%), was used as a scale- and model-independent regularity statistic to quantify the orderliness of ACTH release in each 2-h block (13–15, 22). Higher ApEn denotes greater disorderliness of the secretion process, and conversely for low ApEn. Mathematical models and clinical experiments establish that greater pattern regularity signifies heightened feedback control with high sensitivity and specificity (both >90%) (16, 23, 24).

**Statistical analysis**

Two-way ANOVA in a 4 × 3 factor repeated-measures design was used to assess the individual and combined (interactive) impact of 2-h time segments (four factors) and drug treatment (three factors) on ACTH and cortisol concentrations, ACTH secretory parameters, and ACTH ApEn. $P < 0.05$ was construed as significant. Data are expressed as the mean ± S.E.M. The significance of any set of six or seven slopes was tested by the chi-square statistic applied to $−2$ times the sum of the natural logarithms of the $P$ values at 1 degree of freedom (25).

**Figure 2** Mean cortisol (A) and ACTH (B) concentrations monitored overnight. Data were segmented into 2-h windows and subjected to two-way ANOVA in a repeated-measures design. Different alphabetic letters denote significant contrasts among time segments independently of treatment (capital letters) and among PLAC, KTCZ, and METY treatments within any given time segment (lower-case letters). Data are the mean ± S.E.M. ($N = 6$ subjects).
Results

Cohort mean cortisol and ACTH concentration time series are depicted in Fig. 1. Visual inspection indicated that both steroidogenic inhibitors were effective in suppressing cortisol and elevating ACTH concentrations. In the PLAC session, ACTH concentrations rose by 2.8-fold and cortisol concentrations by 3.5-fold at 0600–0800 h compared with corresponding ACTH and cortisol values measured in the same subjects at MN-0200 (Fig. 2A and B). Administration of METY and KTCZ reduced cortisol concentrations by 45–60% (MN-0400 h) and 54–77% (0400–0800 h) compared with PLAC responses evaluated at the same times (P < 0.001 treatment effect and P < 0.001 time effect by two-way ANOVA; Fig. 2A). ACTH responses were evaluated in relation to PLAC and drug effects in three ways. First, METY-induced hypocortisolemia increased mean ACTH concentrations during the successive 2-h intervals MN-0200, 0200–0400, 0400–0600, and 0600–0800 h by 1.5-, 2-, 4-, and 12-fold respectively, compared with time-matched effects of PLAC. Analogous KTCZ effects were 1.3-, 1.7-, 3.3-, and 7.0-fold compared with time-matched PLAC (P < 0.001 for both drug and time effects and P < 0.001 for drug×time interaction; Fig. 2B). The data document significant and comparable disinhibition of negative feedback after 0400 h by both steroidogenic inhibitors. Second, exposure to METY and KTCZ augmented mean 0600–0800 h ACTH concentrations by 34- and 20-fold respectively, compared with exposure to PLAC during the early-night interval of MN-0200 h (P < 0.001). Third, METY and KTCZ elevated mean ACTH concentrations at 0600–0800 h by 22- and 25-fold over those measured at MN-0200 h under the same drug treatment. Thus, ACTH feedforward during overnight hypocortisolemia increases multifold principally between 0400 h and 0800 h.

Deconvolution analysis of each 8-h time series established that elevated morning ACTH concentrations result primarily from greater pulsatile rather than basal ACTH release (P < 0.001; Fig. 3). In particular, mean pulsatile ACTH secretion over the 8-h session increased markedly and similarly after administration of METY (8.3-fold) and KTCZ (5.3-fold) compared with PLAC (both contrasts P < 0.001). Augmented pulsatile secretion in turn was due to both an 8.0- (METY) and a 4.2-fold (KTCZ) increase in ACTH secretory-burst mass (P < 0.001) for both drug and time effects and P < 0.001 for their difference). There was a lesser 1.33-fold stimulatory effect of KTCZ on ACTH secretory-burst frequency (P = 0.047) and a nonsignificant 1.28-fold effect of METY (P = 0.11). Basal ACTH secretion was 5.7 ± 17 ng/l per 8 h, and rose by 3.4-fold during METY administration (P = 0.020) and 2.7-fold during KTCZ administration (P = 0.052). The foregoing responses were selective, because ACTH half-life, secretory-burst

<table>
<thead>
<tr>
<th>Parameter</th>
<th>PLAC (N=6)</th>
<th>KTCZ (N=7)</th>
<th>METY (N=7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Half-life (min)</td>
<td>21 ± 1.1</td>
<td>22 ± 0.80</td>
<td>22 ± 0.70</td>
</tr>
<tr>
<td>Mode of secretory burst (min)</td>
<td>16 ± 1.7</td>
<td>17 ± 1.6</td>
<td>17 ± 1.6</td>
</tr>
<tr>
<td>Variability of pulsing (γ)</td>
<td>4.3 ± 1.8</td>
<td>2.6 ± 0.36</td>
<td>2.9 ± 0.65</td>
</tr>
</tbody>
</table>

Data are the mean ± s.e.m.
shape and interpulse-interval variability did not change (Table 1). The time dependence of augmented ACTH secretory-burst size was highly significant after each of PLAC, KTCZ, and METY administration (all \( P < 0.001 \); Fig. 4A). Conversely, overnight ACTH interburst-interval lengths declined significantly (\( P < 0.001 \)) during PLAC and KTCZ but not METY administration (Fig. 4B).

Postulated changes in feedback onto ACTH were assessed by ApEn analysis. Lower ApEn denotes greater feedback coordination (Methods). Two-way ANOVA revealed a prominent overnight decline in ACTH ApEn (\( P = 0.021 \) a drug-specific effect \( P = 0.001 \)), and no interaction between time and drug (\( P = 0.14 \); Fig. 5A). The most prominent change occurred in the METY session, indicating that a normal overnight rise in plasma cortisol concentrations is not required to mediate the ApEn decline. Greater regularity (lower ApEn) was due to more reproducible ACTH secretory-burst mass sequences (\( P = 0.033 \)) rather than to more regular interpulse intervals (Fig. 5B).

**Discussion**

The present investigation combined deconvolution analysis and ApEn estimates with a hypocortisolemic clamp to appraise the mechanisms that regulate ACTH secretion across the nighttime transition from nadir to zenith cortisol production in healthy men. The rationale for using two pharmacologic agents is that either could have a nonspecific effect, but it is unlikely that both would have the same nonspecific effect. Congruity of outcomes with structurally distinct inhibitors provides strong corroboration of the role of hypocortisolemia per se. The collective data indicate that i) glucocorticoid negative feedback on pulsatile ACTH secretion normally increases overnight after 0200 h; ii) hypothalamic feedforward increases after 0400 h and more markedly than feedback; and iii) time of night and hypocortisolemia together determine coordinated hypothalamic drive of ACTH secretion.

A significant unexpected finding was that ApEn declined overnight with the lowest values reached by 0400–0600 h in the METY group, denoting maximal feedforward coordination at this time. The decline in ApEn was intermediate for KTCZ. Lower ApEn in biological and mathematical ensemble systems signifies greater negative feedback and/or more coordinated feedforward inputs (16, 17). The fact that ACTH ApEn declined when cortisol concentrations fell under drug-induced feedback withdrawal indicates that cortisol concentrations are not the sole determinant of feedforward-dependent ACTH secretory regularity. One plausible organizing signal is somatostatin, which inhibits CRH and to a lesser degree AVPs stimulation of ACTH release (26–28). The role of AVP is putatively
most evident in stress. Greater hypothalamic somatostatin outflow may occur following deep sleep, since growth hormone (GH) responses to a fixed dose of GHRH are then inhibited (29). In sum, ACTH regularity enhancement detected by ApEn might reflect enhanced coordination between stimulation by CRH (and AVP) and inhibition by somatostatin (30, 31). Interpulse secretion of somatostatin, a peptide that selectively blocks secretory-vesicle release, would favor corticotropic accumulation of exocytotic granules for discharge before the next CRH (or AVP) pulse. This concept could explain the concomitant increase in ACTH secretory-burst mass and decrease in ApEn observed between 0400 h and 0800 h.

Hypocortisolemia selectively augmented nighttime ACTH secretory-burst mass (by 5.1- to 7.1-fold) and in lesser measure frequency (by 1.3-fold). By contrast, ACTH pulse-time regularity, ACTH half-life, and ACTH secretory-burst shape were not affected by hypocortisolemia. A larger 24-h study also found no evident regulation of ACTH pulsing regularity (11). Exploratory regression analysis revealed no consistent effect of body-mass index on any secretory measures, except for an unexplained negative correlation between basal ACTH secretion and body mass index in the KTCZ group only.

Few studies have evaluated ACTH secretion across the nighttime cortisol nadir. The present analyses show that reduction of cortisol concentrations by adrenal steroidogenic blockade with METY between 0200 and 0400 h stimulates ACTH secretion by 2.0-fold compared with PLAC administered at the same time. Thus, diurnally low cortisol concentrations continue to repress ACTH secretion even when the corticotropic axis is minimally active. Hypocortisolemia imposed by METY during the interval 0600–0800 h amplified mean ACTH concentrations by 34-fold with respect to the PLAC-associated nadir (MN-0200 h), 12-fold over the contemporaneous (0600-0800 h) PLAC control, and 22-fold over the METY nadir (MN-0200 h). We postulate that the 34-fold increase across the nighttime reflects both feedback dis inhibition and strong feedforward drive. In this model, 12-fold disinhibition of ACTH output over the nighttime-matched PLAC response indicates the existence of significant negative feedback after the MN cortisol nadir, whereas 22-fold augmentation of ACTH secretion over the MN low-cortisol milieu reflects prominent feedforward at 0600–0800 h. These data are congruent with the clinical principles of minimizing ACTH suppression by administering synthetic glucocorticoids once daily at midnight and testing feedback escape over the same interval.

Little is known about the regulation of basal (nonpulsatile) ACTH secretion. Available evidence suggests that constitutive peptide release may reflect a low frequency of partial emptying of secretory vesicles at the plasma membrane (32, 33). Deconvolution analysis predicted a 3.4-fold rise in basal ACTH secretion during METY compared with PLAC administration. The effect of KTCZ, which lowered cortisol less markedly, was less prominent, suggesting that reduced cortisol availability augments basal ACTH secretion.

In conclusion, experimentally imposing hypocortisolemia via structurally distinct drugs unmasks (a) cortisol feedback-dependent regulation of ACTH secretory-burst mass and (b) time of night-dependent regulation of both ACTH secretory-burst mass and the orderliness of the ACTH secretion process in healthy men. These outcomes are consistent with a dynamic model in which both cortisol feedback and hypothalamic feedforward change overnight. If this model is valid, then corticotropic-axis pathophysiology such as late-day hypercortisolemia in fasting, alcoholism, depression and aging (34–37), might arise from disruption of nighttime regulatory mechanisms.

Declaration of interest

The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.
References


12 Veldhuis JD, Iranmanesh A, Johnson ML & Lizarralde G. Twenty-four hour rhythms in plasma concentrations of adrenocortical hormones are generated by distinct amplitude and/or frequency modulation of underlying pituitary secretory bursts. Journal of Clinical Endocrinology and Metabolism 1990 71 1616–1623.


18 Keenan DM, Chattopadhyay S & Veldhuis JD. Composite model of adrenocorticotropin secretory-burst shape, frequency and mass modulation of underlying pituitary secretory bursts. Hormones are generated by distinct amplitude and/or frequency effects on ACTH secretion in humans. Journal of Clinical Investigation 1979 64 4028–4033.

Received 24 July 2008
Accepted 29 July 2008